There is a teenager I still think about whenever we talk about asthma awareness. The young patient had been taken to hospital several times in one year for breathlessness, wheezing and cough, especially at night or after exercise. Each time, the family did what they believed was right: they reached for the familiar blue inhaler. It helped for a while, so naturally they thought asthma was under control. But it was not. What the family had never fully understood was that asthma is not only about sudden tightening of the airways. Asthma is also about inflammation. Relief was being treated. The disease itself was not.
That is why this year’s World Asthma Day theme speaks so strongly to me: “Access to anti-inflammatory inhalers for everyone with asthma – still an urgent need.” It is a powerful reminder that asthma care has changed, but access has not changed nearly enough. Globally, asthma affects more than 260 million people and causes over 450,000 deaths every year, most of them preventable. GINA continues to emphasize that people with asthma need inhaled corticosteroid-containing treatment, ideally through a 2-in-1 inhaler that gives both relief and anti-inflammatory treatment.